Literature DB >> 25897147

Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.

Harvey D White1, Cynthia M Westerhout2, Karen P Alexander3, Matthew T Roe3, Kenneth J Winters4, Derek D Cyr5, Keith Aa Fox6, Dorairaj Prabhakaran7, Judith S Hochman8, Paul W Armstrong9, E Magnus Ohman3.   

Abstract

AIMS: Little is known regarding consequences of frailty in patients with acute coronary syndrome (ACS). We assessed the associations of frailty and outcomes in ACS patients who were participating in a clinical trial. METHODS AND
RESULTS: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial randomized 9326 patients planned for medical management to prasugrel or clopidogrel. The primary endpoint was a composite of cardiovascular death, myocardial infarction (MI), or stroke over a period of 30 months. A frailty score based upon the Fried score was self-reported at baseline in patients aged ⩾65 years. Five frailty questions were recorded for 4996/5102 (97.9%) patients: 72.3% were classified as not-frail (0 items), 23.0% as pre-frail (1-2 items), and 4.7% as frail (⩾3 items). Increasing frailty score was associated with older age, diabetes, and higher Global Registry of Acute Coronary Events (GRACE) scores. Frailty was associated with a higher unadjusted incidence of the primary endpoint (pre-frail vs not-frail: 29.2% vs 23.1%; hazard ratio [HR]: 1.39; 95% confidence interval [CI]: 1.19-1.61; p<0.001; frail vs not-frail: 39.7% vs 23.1%; HR: 1.76; 95% CI: 1.36-2.28; p<0.001), and all-cause mortality (pre-frail vs not-frail: 21.7% vs 15.0%; HR: 1.45; 95% CI: 1.22-1.73; p<0.001; frail vs not-frail: 30.2% vs 15.0%; HR: 1.98; 95% CI: 1.47-2.68; p<0.001). After adjustment for baseline characteristics and GRACE covariates, frailty remained independently associated with the primary endpoint: pre-frail vs not-frail, HR: 1.33; 95% CI: 1.15-1.54; p<0.001; frail vs not-frail, HR: 1.52; 95% CI: 1.18-1.98; p=0.002. There was no association of frailty with bleeding.
CONCLUSION: Frailty is associated with the composite of cardiovascular death, MI, or stroke. Frailty assessment contributes to risk prediction and adds to the GRACE score. © The European Society of Cardiology 2015.

Entities:  

Keywords:  Frailty; acute coronary syndrome; clinical trial; elderly; outcome assessment

Mesh:

Substances:

Year:  2015        PMID: 25897147     DOI: 10.1177/2048872615581502

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  27 in total

1.  Frailty is an independent prognostic marker in elderly patients with myocardial infarction.

Authors:  Gonzalo Luis Alonso Salinas; Marcelo Sanmartin; Marina Pascual Izco; Luis Miguel Rincon; Pablo Pastor Pueyo; Alvaro Marco Del Castillo; Alberto Garcia Guerrero; Pedro Caravaca Perez; Alejandro Recio-Mayoral; Asuncion Camino; Manuel Jimenez-Mena; José Luis Zamorano
Journal:  Clin Cardiol       Date:  2017-07-16       Impact factor: 2.882

2.  Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes.

Authors:  Alexander C Fanaroff; Derek Cyr; Megan L Neely; Jeffery Bakal; Harvey D White; Keith A A Fox; Paul W Armstrong; Renato D Lopes; E Magnus Ohman; Matthew T Roe
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-12

3.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

4.  A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale.

Authors:  Puneeta Tandon; Navdeep Tangri; Lesley Thomas; Laura Zenith; Tahira Shaikh; Michelle Carbonneau; Mang Ma; Robert J Bailey; Saumya Jayakumar; Kelly W Burak; Juan G Abraldes; Amanda Brisebois; Thomas Ferguson; Sumit R Majumdar
Journal:  Am J Gastroenterol       Date:  2016-08-02       Impact factor: 10.864

5.  Long-Term Survival after Invasive or Conservative Strategy in Elderly Patients with non-ST-Elevation Myocardial Infarction: A Prospective Cohort Study.

Authors:  Kristin Marie Kvakkestad; Jon Michael Gran; Jan Eritsland; Charlotte Holst Hansen; Eigil Fossum; Geir Øystein Andersen; Sigrun Halvorsen
Journal:  Cardiology       Date:  2019-11-05       Impact factor: 1.869

6.  Frailty Assessment in Heart Failure: an Overview of the Multi-domain Approach.

Authors:  Julee McDonagh; Caleb Ferguson; Phillip J Newton
Journal:  Curr Heart Fail Rep       Date:  2018-02

7.  Five-year clinical outcomes in patients with frailty aged ≥75 years with non-ST elevation acute coronary syndrome undergoing invasive management.

Authors:  Hanna Ratcovich; Benjamin Beska; Greg Mills; Lene Holmvang; Jennifer Adams-Hall; Hannah Stevenson; Murugapathy Veerasamy; Chris Wilkinson; Vijay Kunadian
Journal:  Eur Heart J Open       Date:  2022-05-16

8.  Comparison of the prognostic value of frailty assessment tools in patients aged ≥ 65 years hospitalized in a cardiac care unit with acute coronary syndrome.

Authors:  Wojciech Nowak; Ilona Kowalik; Małgorzata Kuzin; Agnieszka Krauze; Anna Mierzyńska; Ewa Sadowy; Kamil Marcinkiewicz; Janina Stępińska
Journal:  J Geriatr Cardiol       Date:  2022-05-28       Impact factor: 3.189

Review 9.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

10.  Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Maurizio Giuseppe Abrignani; Marco Ambrosetti; Nadia Aspromonte; Gabriella Barile; Roberto Caporale; Giancarlo Casolo; Emilia Chiuini; Andrea Di Lenarda; Pompilio Faggiano; Domenico Gabrielli; Giovanna Geraci; Alessio Gaetano La Manna; Aldo Pietro Maggioni; Alfredo Marchese; Ferdinando Maria Massari; Gian Francesco Mureddu; Giuseppe Musumeci; Federico Nardi; Antonio Vittorio Panno; Roberto Franco Enrico Pedretti; Massimo Piredda; Enrico Pusineri; Carmine Riccio; Roberta Rossini; Fortunato Scotto di Uccio; Stefano Urbinati; Ferdinando Varbella; Giovanni Battista Zito; Leonardo De Luca
Journal:  Eur Heart J Suppl       Date:  2018-05-31       Impact factor: 1.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.